Price movement over the last 24 hours
ASML Holding NV vs Centene Corp — how do they compare? ASML Holding NV trades at $1,772.62 (market cap $688.66B), while Centene Corp trades at $68 (market cap $33.26B). The key difference: ASML Holding NV is far larger — about 20.7× Centene Corp's market cap, and ASML Holding NV pays a 0.49% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| ASML | CNC | |
|---|---|---|
Market Cap | $688.66B | $33.26B |
Sector | Technology | Health |
52-Week High | $1.99K | $68.34 |
52-Week Low | $689.63 | $25.21 |
Enterprise Value | $682.20B | $25.89B |
Dividend Yield | 0.49% | — |
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,797.32, down 0.38% on the day, with technical indicators showing a bullish trend despite recent volatility. The company reported strong Q1 2026 earnings that beat expectations, with revenue reaching $32.67B in 2025 and net income margins of 29.71%. Analyst consensus remains strongly positive with 56.82% buy ratings and a $2,210 price target, though elevated valuation ratios (P/E 61.03) warrant caution.
ASML maintains a dominant position in advanced semiconductor equipment with robust profitability and growth prospects driven by AI infrastructure demand. Key risks include China export restrictions, competitive pressures, and high valuation multiples. The stock offers exposure to critical chip manufacturing technology but requires monitoring of earnings execution and geopolitical developments.
Centene (CNC) trades at $67.35, down 0.37% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.06 and P/S of 0.17, but faces profitability challenges with a negative net income margin of -3.25% for 2025. Recent positive developments include the renewal of a key Illinois Medicaid contract and consistent earnings beats in recent quarters, supporting a strong analyst consensus with 61% buy ratings.
The outlook for CNC hinges on successful margin recovery initiatives and cost management. Investment opportunities lie in its undervalued metrics and stable revenue base, but risks include persistent negative profitability, regulatory pressures in healthcare, and execution challenges in improving medical cost controls. The consensus price target of $63.36 suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →